AcneFree Is Latest In Rash Of NAD Decisions Against University Medical
This article was originally published in The Tan Sheet
Executive Summary
University Medical Pharmaceuticals continues to have trouble supporting its competitive marketing claims to the satisfaction of the National Advertising Division
You may also be interested in...
In Brief
Okla. and Ala. limit PSE sales while Colo. and Hawaii consider NPLEx; Abbott, Biocon team on Indian nutrition R&D; Bunge leaves Solae stake to DuPont; Valeant buys AcneFree; more news In Brief.
NAD takes issue with University Medical
The National Advertising Division recommends University Medical Pharmaceuticals discontinue claims that compare the effects of its WrinkleFree Eyes to those of Botox, the Council of Better Business Bureaus division says Aug. 19. NAD says the firm should discontinue claims such as, "Clinically proven to reduce wrinkle appearance up to 85 percent in only 20 minutes" and "Truly effective topical alternative to Botox" because of a lack of evidence. NAD asks that the firm remove before-and-after photographs because the lighting, posing and cosmetic application are different in the first photo. The firm said the photos are not misleading. The Irvine, Calif., firm said it is disappointed with NAD's decision, but will consider the recommendations and modify its advertising accordingly
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC